



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Donoho et al.

Application No.: 09/733,387

Filed: December 7, 2000

Title: Novel Human Membrane Proteins and Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0104-USA

Group Art Unit: 1646

Examiner: R. Li

RECEIVED

NOV 29 2002

#12  
A.G.  
1/15/03

Assistant Commissioner for Patents  
Arlington, VA 22202

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

— under 37 CFR 1.97(b), or  
(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

X under 37 CFR 1.97(c) together with either a:

— Certification under 37 CFR 1.97(e), or

X a \$180.00 fee under 37 CFR 1.17(p), or

(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

01/15/2003 GTRAMEL 00000006 500892 09733387

01 FC:1806 180.00 CH under 37 CFR 1.97(d) together with a:

— Certification under 37 CFR 1.97(e), and

— a petition under 37 CFR 1.97(d)(2)(ii), and

— a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

X Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.



24231

PATENT TRADEMARK OFFICE

The relevance of the attached references is that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

November 21, 2002  
Date

*Lance K. Ishimoto by David W. Higler* *REG. NO. 41,866*  
Lance K. Ishimoto Reg. No. 41,866

LEXICON GENETICS INCORPORATED  
8800 Technology Forest Place  
The Woodlands, TX 77381  
(281) 863-3333



24231

PATENT TRADEMARK OFFICE